Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel. This presentation comes at a pivotal time for the company as it advances its lead candidate, ENV-105, through clinical development.
The significance of this announcement lies in the platform it provides Kairos Pharma to communicate its scientific strategy and clinical milestones to the investment community. H.C. Wainwright conferences are well-attended by institutional investors, analysts, and industry stakeholders, making this an opportunity for the company to enhance its visibility and potentially attract strategic partnerships or funding. For a clinical-stage biotech, such exposure is critical to sustaining research momentum and moving therapies from bench to bedside.
Kairos Pharma is distinguished by its use of structural biology to address two major challenges in oncology: drug resistance and immune suppression. The company's lead candidate, ENV-105, is an antibody designed to target CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach has the potential to fill an unmet medical need, as resistance to existing treatments remains a leading cause of cancer mortality.
The presentation at the conference will likely detail recent progress, including any clinical trial updates, preclinical data, and future development plans. Investors will be keen to understand the timeline for regulatory milestones and the potential market opportunity for ENV-105. Given that CD105 is implicated in various cancers, the addressable patient population could be substantial, which may interest investors seeking high-growth opportunities in oncology.
Moreover, the conference participation underscores the company's commitment to transparent communication with its shareholders. By presenting at a prominent event, Kairos Pharma is signaling confidence in its pipeline and its ability to deliver value. The company's focus on overcoming drug resistance is particularly relevant in an era where many cancer therapies face diminishing returns due to acquired resistance.
In addition to the conference presentation, investors can stay updated on Kairos Pharma's latest news through the company's newsroom at https://ibn.fm/KAPA. The company also maintains a presence in Los Angeles, California, where it conducts its research and development activities.
The broader context of this announcement is the growing need for innovative cancer treatments. As the global cancer burden continues to rise, therapies that can enhance the efficacy of existing drugs are of immense value. Kairos Pharma's approach of targeting CD105 offers a novel mechanism that could complement standard care regimens, potentially improving outcomes for patients who have limited options.
For more information about the conference and Kairos Pharma's participation, interested parties can refer to the full press release at https://ibn.fm/NrBQD. The company's participation in such a prestigious event is a testament to its progress and the potential of its science.
